MedPath

Penwest Pharmaceuticals Co.

Penwest Pharmaceuticals Co. logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
1991-01-01
Employees
39
Market Cap
-
Website

Clinical Trials

3

Active:1
Completed:1

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation

Phase 2
Terminated
Conditions
Neuromuscular Disease
Interventions
Drug: A0001 (alpha-tocopherolquinone)
Drug: Placebo
First Posted Date
2010-02-24
Last Posted Date
2011-04-22
Lead Sponsor
Penwest Pharmaceuticals Co.
Target Recruit Count
30
Registration Number
NCT01074359
Locations
🇬🇧

University of Newcastle upon Tyne, Newcastle, Framlington Place, United Kingdom

Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

Phase 2
Completed
Conditions
Friedreich's Ataxia
Interventions
First Posted Date
2009-12-21
Last Posted Date
2011-04-22
Lead Sponsor
Penwest Pharmaceuticals Co.
Target Recruit Count
42
Registration Number
NCT01035671
Locations
🇺🇸

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.